ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP) Files An 8-K Results of Operations and Financial Condition

ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Conditions

Story continues below

On May 10, 2018, Adamis Pharmaceuticals Corporation (the “Company”) announced certain financial results for the three months ended March 31, 2018, and provided a business update concerning certain matters. A copy of the Company’s press release announcing this information and certain other information is attached hereto as Exhibit 99.1.

The information furnished in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits

Exhibit No.

Description
99.1 Press Release issued May 10, 2018.


Adamis Pharmaceuticals Corp Exhibit
EX-99.1 2 ex99-1.htm PRESS RELEASE   ADAMIS PHARMACEUTICALS CORPORATION 8-K   Exhibit 99.1 Adamis Pharmaceuticals Announces First Quarter 2018 Financial Ressults and Business Update   San Diego,…
To view the full exhibit click here

About ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP)

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

An ad to help with our costs